Durect Seeks Posidur Partner As It Continues Without A Marketed Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma is hoping to sign another partner to help finish developing the injectable pain medication and bring it to market after FDA issued a “complete response” letter in February.